Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00762229 · ClinicalTrials.gov registry record · NA
Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)
A NA study, sponsored by Bronx VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT00762229 is a NA study that has completed, run by Bronx VA Medical Center. The registered enrollment target is 39 participants.
The verdict
NCT00762229, a NA study, has completed, sponsored by Bronx VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.
Interventions
- DRUG Ezetimibe 10 mg
- DRUG Ezetimibe 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00762229
The ClinicalTrials.gov registry entry for NCT00762229 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bronx VA Medical Center, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ezetimibe 10 mg is the first listed.
NCT00762229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00762229 about?
NCT00762229 is a clinical study titled "Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)". The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.
What is the current status of trial NCT00762229?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2007-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00762229?
The interventions under investigation include: Ezetimibe 10 mg (DRUG), Ezetimibe 5 mg (DRUG).
Who is sponsoring clinical trial NCT00762229?
This trial is sponsored by Bronx VA Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.